Document:

Prepared by MerrillDirect

Exhibit
10.33

LIFE
INSURANCE

ENDORSEMENT METHOD SPLIT DOLLAR
PLAN

AGREEMENT

 

	Insurer:	ING
  Southland Life Insurance Company
	 	Union
  Central Life Insurance Company
	 	 
	Policy
  Number:	0660012184
	 	U200001016
	 	 
	Bank:	Clovis
  Community Bank
	 	 
	Insured:	Shirley
  Wilburn
	 	 
	Relationship
  of Insured to Bank:	Executive

The respective rights and duties of the
Bank and the Insured in the above-referenced policy shall be pursuant to the
terms set forth below:

I.           DEFINITIONS

Refer
to the policy contract for the definition of all terms in this Agreement.

II.          POLICY TITLE AND OWNERSHIP

Title
and ownership shall reside in the Bank for its use and for the use of the
Insured all in accordance with this Agreement. 
The Bank alone may, to the extent of its interest, exercise the right to
borrow or withdraw on the policy cash values. 
Where the Bank and the Insured (or assignee, with the consent of the
Insured) mutually agree to exercise the right to increase the coverage under
the subject Split Dollar policy, then, in such event, the rights, duties and
benefits of the parties to such increased coverage shall continue to be subject
to the terms of this Agreement.

III.        BENEFICIARY DESIGNATION RIGHTS

The
Insured (or assignee) shall have the right and power to designate a beneficiary
or beneficiaries to receive the Insured’s share of the proceeds payable upon
the death of the Insured, and to elect and change a payment option for such
beneficiary, subject to any right or interest the Bank may have in such
proceeds, as provided in this Agreement.

IV.        PREMIUM PAYMENT METHOD

The
Bank shall pay an amount equal to the planned premiums and any other premium
payments that might become necessary to keep the policy in force.

V.         TAXABLE BENEFIT

Annually
the Insured will receive a taxable benefit equal to the assumed cost of
insurance as required by the Internal Revenue Service.  The Bank (or its administrator) will report
to the Insured the amount of imputed income each year on Form W-2 or its
equivalent.

VI.        DIVISION OF DEATH PROCEEDS

Subject
to Paragraphs VII and IX herein, the division of the death proceeds of the
policy is as follows:

	 	A.	Should
  the Insured be employed by the Bank and die before the Executive attains age
  sixty-five (65),the Insured’s beneficiary(ies), designated in accordance
  with Paragraph III, shall be entitled to an amount equal to Four Hundred
  Sixty Six Thousand Dollars and No/00ths ($466,000.00), or one hundred percent
  (100%) of the net at risk insurance portion of the proceeds, whichever amount
  is less.  The net at risk insurance
  portion is the total proceeds less the cash value of the policy.
	 	B.	Should
  the Insured be employed by the Bank, or retired from the Bank, and die on or
  subsequent to attaining the age of sixty-five (65), the Insured’s
  beneficiary(ies), designated in accordance with Paragraph III, shall be
  entitled to an amount equal to the amount as set forth in Exhibit A, attached
  hereto and fully incorporated herein by reference, that corresponds to the
  age of the Insured at the time of death, or one hundred percent (100%) of the
  net at risk insurance portion of the proceeds, whichever amount is less.  The net at risk insurance portion is the
  total proceeds less the cash value of the policy.
	 	C.	Should
  the Insured not be employed by the Bank at the time of his or her death, and
  have been involuntarily terminated from employment with the Bank, and die
  prior to attaining age sixty-five (65), the Insured’s beneficiary(ies),
  designated in accordance with Paragraph III, shall be entitled to the
  percentage as set forth hereinbelow of the proceeds described in Subparagraph
  VI (A) above that corresponds to the age of the Insured at the time of
  termination and the number of full years the Insured had been employed by the
  Bank since the Effective Date of this Agreement. 
  Should the Insured not be employed by the Bank at the time
  of his or her death, and have been involuntarily terminated from employment
  with the Bank, and die subsequent to attaining age sixty-five (65), the
  Insured’s beneficiary(ies) shall be entitled to the following percentage of
  the proceeds described in Subparagraph VI (B) hereinabove:

 

	 	Age	Total Years of
  Employment with the Bank	Vested (to a maximum
  of 100%)
	 	

	

	

	 	58	1	0%
	 	59	2	0%
	 	60	3	40%
	 	61	4	50%
	 	62	5	60%
	 	63	6	80%
	 	64	7	90%
	 	65	8	100%

 

	 	D.	The
  Bank shall be entitled to the remainder of such proceeds.
	 	 	 
	 	E.	The
  Bank and the Insured (or assignees) shall share in any interest due on the
  death proceeds on a pro rata basis as the proceeds due each respectively
  bears to the total proceeds, excluding any such interest.

VII.       DIVISION OF THE CASH SURRENDER VALUE OF THE POLICY

The
Bank shall at all times be entitled to an amount equal to the policy’s cash
value, as that term is defined in the policy contract, less any policy loans
and unpaid interest or cash withdrawals previously incurred by the Bank and any
applicable surrender charges.  Such cash
value shall be determined as of the date of surrender or death as the case may
be.

VIII.     RIGHTS OF PARTIES WHERE POLICY ENDOWMENT OR ANNUITY ELECTION EXISTS

In
the event the policy involves an endowment or annuity element, the Bank’s right
and interest in any endowment proceeds or annuity benefits, on expiration of
the deferment period, shall be determined under the provisions of this
Agreement by regarding such endowment proceeds or the commuted value of such
annuity benefits as the policy’s cash value. 
Such endowment proceeds or annuity benefits shall be considered to be
like death proceeds for the purposes of division under this Agreement.

IX.        TERMINATION
OF AGREEMENT

This
Agreement shall terminate upon the occurrence of any one of the following:

	 	1.	The
  Insured shall leave the employment of the Bank involuntarily prior to two (2)
  full years of employment with the Bank from the Effective Date of this
  Agreement; or
	 	 	 
	 	2.	The
  Insured shall leave the employment of the Bank voluntarily at any time; or
	 	 	 
	 	3.	The
  Insured attains the age of seventy-nine (79); or
	 	 	 
	 	4.	The
  Insured shall be discharged from employment with the Bank for cause.  The term for “cause” shall mean any of the
  following that result in an adverse effect on the Bank: (i) gross negligence
  or gross neglect; (ii) the commission of a felony or gross misdemeanor
  involving moral turpitude, fraud, or dishonesty; (iii) the willful violation
  of any law, rule, or regulation (other than a traffic violation or similar
  offense); (iv) an intentional failure to perform stated duties; or (v) a
  breach of fiduciary duty involving personal profit; or
	 	 	 
	 	5.	Surrender,
  lapse, or other termination of the Policy by the Bank.
	 	 	 
	 	Upon
  such termination, the Insured (or assignee) shall have a fifteen (15) day
  option to receive from the Bank an absolute assignment of the policy in
  consideration of a cash payment to the Bank, whereupon this Agreement shall
  terminate.  Such cash payment referred
  to hereinabove shall be the greater of:
	 	 	 
	 	1.	The
  Bank’s share of the cash value of the policy on the date of such assignment,
  as defined in this Agreement; or
	 	 	 
	 	2.	The
  amount of the premiums which have been paid by the Bank prior to the date of
  such assignment.

If,
within said fifteen (15) day period, the Insured fails to exercise said option,
fails to procure the entire aforestated cash payment, or dies, then the option
shall terminate, and the Insured (or assignee) agrees that all of the Insured’s
rights, interest and claims in the policy shall terminate as of the date of the
termination of this Agreement.

The
Insured expressly agrees that this Agreement shall constitute sufficient
written notice to the Insured of the Insured’s option to receive an absolute
assignment of the policy as set forth herein.

Except
as provided above, this Agreement shall terminate upon distribution of the
death benefit proceeds in accordance with Paragraph VI above.

X.         INSURED’S OR ASSIGNEE’S ASSIGNMENT RIGHTS

The
Insured may not, without the written consent of the Bank, assign to any
individual, trust or other organization, any right, title or interest in the
subject policy nor any rights, options, privileges or duties created under this
Agreement.

XI.        AGREEMENT BINDING UPON THE PARTIES

This
Agreement shall bind the Insured and the Bank, their heirs, successors,
personal representatives and assigns.

XII.       ERISA PROVISIONS

The
following provisions are part of this Agreement and are intended to meet the
requirements of the Employee Retirement Income Security Act of 1974 (“ERISA”):

A.         Named Fiduciary and Plan
Administrator.

The
“Named Fiduciary and Plan Administrator” of this Endorsement Method Split
Dollar Agreement shall be Clovis Community Bank until resignation or removal by
the Board of Directors.  As Named
Fiduciary and Plan Administrator, the Bank shall be responsible for the
management, control, and administration of this Split Dollar Plan as
established herein.  The Named Fiduciary
may delegate to others certain aspects of the management and operation
responsibilities of the Plan, including the employment of advisors and the
delegation of any ministerial duties to qualified individuals.

B.          Funding Policy.

The
funding policy for this Split Dollar Plan shall be to maintain the subject
policy in force by paying, when due, all premiums required.

C.          Basis of Payment of Benefits.

Direct
payment by the Insurer is the basis of payment of benefits under this
Agreement, with those benefits in turn being based on the payment of premiums
as provided in this Agreement.

D.         Claim Procedures.

Claim
forms or claim information as to the subject policy can be obtained by
contacting Benmark, Inc. (800-544-6079). 
When the Named Fiduciary has a claim which may be covered under the
provisions described in the insurance policy, they should contact the office
named above, and they will either complete a claim form and forward it to an
authorized representative of the Insurer or advise the named Fiduciary what
further requirements are necessary.  The
Insurer will evaluate and make a decision as to payment.  If the claim is payable, a benefit check
will be issued in accordance with the terms of this Agreement.

In
the event that a claim is not eligible under the policy, the Insurer will
notify the Named Fiduciary of the denial pursuant to the requirements under the
terms of the policy.  If the Named
Fiduciary is dissatisfied with the denial of the claim and wishes to contest
such claim denial, they should contact the office named above and they will
assist in making inquiry to the Insurer. 
All objections to the Insurer’s actions should be in writing and
submitted to the office named above for transmittal to the Insurer.

XIII.     GENDER

Whenever
in this Agreement words are used in the masculine or neuter gender, they shall
be read and construed as in the masculine, feminine or neuter gender, whenever
they should so apply.

XIV.     INSURANCE COMPANY NOT A PARTY TO THIS AGREEMENT

The
Insurer shall not be deemed a party to this Agreement, but will respect the
rights of the parties as herein developed upon receiving an executed copy of
this Agreement.  Payment or other
performance in accordance with the policy provisions shall fully discharge the
Insurer for any and all liability.

XV.      CHANGE OF
CONTROL

Change
of Control shall be deemed to be the cumulative transfer of more than fifty
percent (50%) of the voting stock of the Bank from the date of this
Agreement.  For the purposes of this
Agreement, transfers on account of deaths or gifts, transfers between family
members, or transfers to a qualified retirement plan maintained by the Bank
shall not be considered in determining whether there has been a Change of
Control.  Upon a Change of Control, if
the Insured’s employment is subsequently terminated, except for cause, then the
Insured shall be one hundred percent (100%) vested in the benefits promised in
this Agreement and, therefore, upon the death of the Insured, the Insured’s
beneficiary(ies) (designated in accordance with Paragraph III) shall receive
the death benefit provided herein as if the Insured had died while employed by
the Bank [See Subparagraphs VI (A) & (B)].

XVI.     AMENDMENT OR REVOCATION

It
is agreed by and between the parties hereto that, during the lifetime of the
Insured, this Agreement may be amended or revoked at any time or times, in
whole or in part, by the mutual written consent of the Insured and the Bank.

XVII.    EFFECTIVE DATE

The
Effective Date of this Agreement shall be April 1, 2001.

XVIII.  SEVERABILITY AND
INTERPRETATION

If
a provision of this Agreement is held to be invalid or unenforceable, the
remaining provisions shall nonetheless be enforceable according to their
terms.  Further, in the event that any
provision is held to be over broad as written, such provision shall be deemed
amended to narrow its application to the extent necessary to make the provision
enforceable according to law and enforced as amended.

XIX.     APPLICABLE LAW

The
validity and interpretation of this Agreement shall be governed by the laws of
the State of California.

XX.      COMPETITION AFTER TERMINATION OF EMPLOYMENT

The
Bank shall not pay any benefit under this Agreement if the Insured, without the
prior written consent of the Bank, engages in, becomes interested in, directly
or indirectly, as a sole proprietor, as a partner in a partnership, or as a
substantial shareholder in a corporation, or becomes associated with, in the
capacity of employee, director, officer, principal, agent, trustee or in any
other capacity whatsoever, any enterprise conducted in the trading area (a 50
mile radius) of the business of the Bank, which enterprise is, or may deemed to
be, competitive with any business carried on by the Bank as of the date of
termination of the Insured’s employment or his retirement.  This section shall not apply following a
Change of Control.

Executed at Clovis, California this 17th
day of April,  2001.

	 	 	CLOVIS
  COMMUNITY BANK
Clovis, California
	 	 	 
	/s/
  Janice H. Neary	 	By:
  /s/ Daniel J. Doyle
	

	 	

	Witness	 	Title  President & CEO
	 	 	 
	 	 	 
	/s/
  Janice H. Neary	 	/s/
  Shirley Wilburn
	

	 	

	Witness	 	Shirley
  Wilburn

 

EXHIBIT A

 

	Age
  of Insured at the Time of Death	 	Amount
  of Death Benefit, or 100% of the net-at-risk, whichever amount is less
	

	 	

	65	 	$455,599.00
	66	 	$443,407.00
	67	 	$429,039.00
	68	 	$412,303.00
	69	 	$392,992.00
	70	 	$370,885.00
	71	 	$345,741.00
	72	 	$317,305.00
	73	 	$285,298.00
	74	 	$249,425.00
	75	 	$209,365.00
	76	 	$164,775.00
	77	 	$115,287.00
	78	 	  $60,504.00
	 	79
  or older	 	$0.00
  and this Agreement  automatically
  terminates
				

 

BENEFICIARY DESIGNATION FORM

FOR LIFE INSURANCE ENDORSEMENT METHOD

SPLIT DOLLAR PLAN AGREEMENT

 

PRIMARY DESIGNATION:

	Name	Address	Relationship
	 	 	 
	

	 	 	 
	

	 	 	 
	

 

SECONDARY (CONTINGENT) DESIGNATION:

	 	 	 
	

	 	 	 
	

	 	 	 
	

 

All sums payable under the Life Insurance
Endorsement Method Split Dollar Plan Agreement by reason of my death shall be
paid to the Primary Beneficiary, if he or she survives me, and if no Primary
Beneficiary shall survive me, then to the Secondary (Contingent) Beneficiary.

 

	

	 	

	Shirley
  Wilburn	 	DatePrepared by MerrillDirect

EXHIBIT
10.1

Confidential treatment requested

COLLABORATION AGREEMENT

This Agreement is
entered into as of June 4, 2001, by and between:

SEATTLE GENETICS, INC.,
a Delaware corporation, having its principal place of business at 22215 26th
Avenue S.E., Suite 3000, Bothell, Washington 98021

(hereinafter
referred to as “SGI”)

and:

EOS BIOTECHNOLOGY, INC.,
a Delaware corporation, having its principal place of business at 225A Gateway
Blvd, S. San Francisco, California 94080

(hereinafter
referred to as “EOS”).

WITNESSETH

             WHEREAS, SGI owns or controls intellectual property rights
relating to certain drug conjugation and linker technology;

             WHEREAS, EOS is currently conducting research and
development programs aimed at the discovery of antigens and the development of
antibodies targeting those antigens;

             WHEREAS, EOS wishes to acquire from SGI exclusive options to
worldwide exclusive licenses under SGI’s patent rights and know-how related to
SGI’s drug conjugation and linker technology;

             WHEREAS, SGI is willing to grant to EOS such exclusive
options in order to allow EOS to evaluate SGI’s drug conjugation and linker
technology for use with certain of EOS’s proprietary antigens and antibodies,
and

             WHEREAS, SGI is willing to grant to EOS such exclusive
licenses, subject to the terms of and conditioned upon this Agreement.

             NOW,
THEREFORE, in consideration of the mutual covenants and obligations set forth
herein, the Parties hereto, intending to be legally bound, agree as follows:

ARTICLE I - DEFINITIONS AND INTERPRETATION

             1.1.       Definitions:  For the purposes of this Agreement the following words and
phrases shall have the following meanings:

                           “ADC”
means any Antibody or Control Antibody that incorporates or uses Drug
Conjugation Technology.

                           “Affiliate”
means, with respect to a Party, any person, corporation or business entity that
directly, or indirectly through one or more intermediaries, controls, is
controlled by, or is under common control with, a Party.  For the purpose of this definition, control
of a corporation or of another business entity shall mean the possession,
directly or indirectly, of the power to direct or cause the direction of the
management or the policies of the entity, whether through the ownership of
voting securities, by agreement or otherwise; provided, however,
that the direct or indirect beneficial ownership of [*] of the voting interests
in, or [*] interest in the equity of, such corporation or other business entity
shall not alone constitute control of such corporation or other business entity.

                           “Agreement”
means this agreement, all amendments and supplements to this Agreement and all
schedules to this Agreement, including the following:

Schedule
A      -            Drug Conjugation Technology Field;

Schedule B       -            Licensed Patents;

Schedule C       -            Research Antigens;

Schedule D      -            ADC Preparation Terms; and

Schedule E       -            SGI In-Licenses

                           “Antibody”
or “Antibodies” means any
monoclonal antibody [*], or fragment thereof, with a unique amino acid sequence
that binds to a Research Antigen or Exclusive Antigen.  By way of clarification, Antibodies with
different amino acid sequences shall be deemed to be different Antibodies,
irrespective of whether they bind to the same Research Antigen or Exclusive
Antigen.

                           “Antigen”
means any [*](including any [*]), [*], compound or other composition, and any
fragment, peptide or epitope thereof, 
to which an antibody binds.

                           “Calendar Quarter” means any of the
three-month periods beginning January 1, April 1, July 1 and
October 1 in any year.

                           “Confidential
Information” has the meaning ascribed to it in Section 10.1. of
this Agreement.

                           “Control
Antibody” shall have the meaning set forth in Section 3.5.

                           “Cost
of Goods” shall mean with respect to Drug Conjugate Materials manufactured and
supplied to EOS (i) if by Third-Parties, [*] in such manufacture and supply of
Drug Conjugate Materials; and (ii) if by SGI or its Affiliates, [*] Percent
([*]%) of the consolidated fully burdened cost of providing such goods or
services which shall be limited to the following factors: [*].

                           “Drug
Conjugate Materials” means research grade small molecular weight
cytotoxic drugs, [*], and linkers for attaching drugs to proteins, specifically
monoclonal antibodies and fragments thereof.

                           “Drug
Conjugation Technology” means drug conjugation chemistry owned or
controlled by SGI, [*] and linker technology for attaching drugs to Antibodies that is the subject matter of the Licensed Patents and SGI Know-How.

                           “Effective Date” means the date of this
Agreement.

                           “EOS
Patents” shall have the meaning set forth in Section 11.2.2.

                           “Events
of Force Majeure” shall have the meaning set forth in Article 17.

                           “Exclusive
Antigen” shall have the meaning set forth in Section 4.2.1.

                           “Exclusive
License” has the meaning ascribed to it in Section 4.2.1 of this Agreement.

                           “Field” means any and all [*], unless mutually agreed to by
the Parties and set forth in Schedule A.

                           “First
Commercial Sale” means, in each country of the Territory, the first
commercial sale, where sale means when delivered, billed out, or invoiced,
whichever comes first, of a Product by EOS, its Affiliates or Sublicensees to a
Third-Party (other than a Sublicensee) following Regulatory Approval in the
country in which the sale is to be made.

                           “Improvements”
means all patentable or non-patentable inventions, discoveries, technology and
information of any type whatsoever, including compositions, chemical compounds,
biological materials, methods, processes, technical information, knowledge,
experience and know-how which (i) [*], (ii) [*], or (iii) [*].

                           “Initial
Research Program Fee” has the meaning ascribed to it in Section 3.4(a) hereof.

                           “Initiation” means, with respect to a human clinical trial, the
treatment of the first patient with a Product pursuant to a clinical protocol
of the specified clinical trial.

                           “Licensed
Patents” means:

                                        (i)          any [*] patents and patent applications listed in Schedule B
to this Agreement;

                                        (ii)         any patents and patent applications covering [*],
and covering [*];

                                        (iii)        any [*] patents issued from any patent applications referred
to above and any [*] patents issued from a patent application filed in any
country in the Territory which corresponds to a patent or patent application
identified above; and

                                        (iv)       any reissues, confirmations, renewals, extensions,
counterparts, divisions or continuations issued, assigned or licensed to SGI of
or relating to the patents or patent applications identified above.

                           “Net Sales” means the gross amount received
by EOS, its Affiliates and Sublicensees from the sale or other disposition of
Products to Third-Parties (other than Sublicensees), less the sum of the
following deductions for amounts actually incurred related to said sale or
other disposition:

                                        (i)          normal, customary trade discounts (including volume
discounts), credits and allowances and adjustments for rejections, recalls and
returns;

                                        (ii)         cost of freight and insurance, sales, use, excise, value
added and similar taxes, surcharges, duties and other governmental charges
(other than income tax) imposed on the sale and included in the gross amount
charged to customers;

                                        (iii)        normal, customary wholesaler chargebacks and rebates
(including rebates to government agencies and government mandates and managed
healthcare negotiated rebates); and

                                        (iv)       retroactive price reductions; provided that no deduction for
retroactive price reductions shall be taken for the sale or disposition of
Products incorporating technology sublicensed under the [*].

                           “New
Technologies” has the meaning ascribed in Section 4.3 hereof.

                           “Option”
means, with respect to each Research Antigen, the exclusive option granted by
SGI to EOS pursuant to the provisions of Section 4.1 hereof to obtain an
Exclusive License under Section 4.2 hereof.

                           “Option
Exercise Fee” has the meaning ascribed to it in Section 4.1.2
hereof.

                           “Option
Period” means, with respect to each Research Antigen, the period
commencing as of (i) the date that [*],
or (ii) the date that [*], and
continuing for a period of [*] ([*]) [*] unless terminated earlier pursuant to
the provisions of Article 15 herein.

                           “Parties”
means EOS and SGI, and “Party” means any one of them.

                           “Phase I
Clinical Trial” means a clinical study in subjects to evaluate the
pharmacokinetic and pharmacodynamic properties, maximum tolerated dose, dosing interval,
and absorption, distribution, metabolism and excretion of a candidate drug.

                           “Phase
II Clinical Trial” means a controlled dose ranging clinical trial to
evaluate the efficacy and safety of a candidate drug in the targeted patient
population and to define the optimal dosing regimen.

                           “Phase
III Clinical Trial” means a series of controlled, pivotal,
multi-center clinical trials, involving patients with the disease or condition
of interest to obtain sufficient efficacy and safety data to support regulatory
submissions and labeling of a candidate drug.

                           “Phase
IV Clinical Trial” means human clinical trials conducted for
inclusion in (i) that portion of the FDA submission and approval process which
provides for continued trials of a Product after Regulatory Approval has been
achieved (such trials may be designed to provide information that will optimize
or expand use of the Product, provide information from additional drug
interaction, dose-response and safety studies, or provide pharmacoeconomic, epidemiological,
comparative efficacy or other data from studies in a therapeutic use
environment) and (ii) foreign equivalents thereof.

                           “Product”
means any and all products where the manufacture, sale or use of such products
would have constituted a misappropriation of Drug Conjugation Technology, SGI
Know-How, Improvements or New Technologies, and/or an infringement of the
Licensed Patents but for the licenses granted in this Agreement.

                           “Regulatory Approval” means final regulatory approval (including,
where applicable, pricing approval in the event that actual sales do not take
place before such approval) required to market a Product for a disease or
condition in accordance with the applicable laws and regulations of a given
country.  In the United States, its
territories and possessions, Regulatory Approval means approval of a Biologics
License Application (“BLA”) or its equivalent by the United States Food
and Drug Administration (“FDA”), or successor agency.

                           “Research
Antigen” means any Antigen that is [*] designated a “Research Antigen”
under this Agreement pursuant to Section 2.1.

                           “Research
Program” means the research program conducted pursuant to
Article 3.

                           “Research
Program Term” shall mean the term of the Research Program set forth
in Section 3.3.

                           “Royalty
Term” means, on a Product-by-Product and country-by-country basis,
the period of time equal to the longer of (a) [*] ([*])[*] from the date
of First Commercial Sale of the Product in such country or (b) the term
for which a Valid Patent Claim directly relating to the Product in such country
remains in effect.

                           “Second
Research Program Fee” has the meaning ascribed to it in
Section 3.4(b) hereof.

                           “SGI
In-Licenses” means the following agreements between SGI and the
indicated Third-Parties: (i) the License Agreement between [*] (“[*]”)
and SGI dated [*], as amended (the “[*]”), (ii) the License Agreement
between [*] (“[*]”) and SGI dated [*], as amended (the “[*]”),
and (iii) [*].

                           “SGI
Know-How” means any and all technical information, processes, formulae, data,
engineering, inventions, chemical compounds, know-how and trade secrets, in
each case that is Confidential Information according to Article 10, that
relate to the Drug Conjugation Technology and which have
been, or hereafter are during the term of this Agreement, either developed by
SGI or its Affiliates, or have been acquired by SGI or its Affiliates with the
right to grant licenses, immunities or other rights thereon.

                           “SGI
Technology” means the Licensed Patents, the SGI Know-How,
Improvements to the extent included in this Agreement pursuant to Section 4.3.1
and New Technologies to the extent included in this Agreement pursuant to
Section 4.3.2.

                           “Sublicensees”
means any person acting pursuant to a sublicense granted to it by EOS or its
Affiliates under the terms of this Agreement.

                           “Term”
has the meaning ascribed to it in Article 15

                           “Territory”
means all countries in the world.

                           “Third-Party”
means any person other than EOS, SGI and their respective Affiliates.

                           “Third
Research Program Fee” has the meaning ascribed to it in Section 3.4(c) hereof.

                           “Valid Patent Claim” means a claim of an
issued and unexpired patent included in Licensed Patents or EOS Patents which
has not been held permanently revoked, unenforceable or invalid by a decision
of a court or other governmental agency of competent jurisdiction, unappealable
or unappealed within the time allowed for appeal, and which has not been
admitted to be invalid or unenforceable through reissue or disclaimer or
otherwise.

             1.2.       Certain Rules of
Interpretation in this Agreement and the Schedules.

                           (a)         Unless
otherwise specified, all references to monetary amounts are to United States of
America currency (US Dollars);

                           (b)        The
descriptive headings of Articles and Sections are inserted solely for
convenience of reference and are not intended as complete or accurate
descriptions of the content of such Articles or Sections;

                           (c)         The
use of words in the singular or plural, or with a particular gender, shall not
limit the scope or exclude the application of any provision of this Agreement
to such person or persons or circumstances as the context otherwise permits;

                           (d)        The
words “include” and “including” have the inclusive meaning frequently
identified with the phrases “without limitation” and “but not limited to”;

                           (e)         Whenever
a provision of this Agreement requires an approval or consent by a Party to
this Agreement and notification of such approval or consent is not delivered
within the applicable time limit, then, unless otherwise specified, the Party
whose approval or consent is required shall be conclusively deemed to have
withheld its approval or consent;

                           (f)         Unless
otherwise specified, time periods within or following which any payment is to
be made or act is to be done shall be calculated by excluding the day on which
the period commences and including the day on which the period ends and by
extending the period to the next business day following if the last day of the
period is not a business day in the jurisdiction of the Party to make such
payment or do such act; and

                           (g)        Whenever
any payment is to be made or action to be taken under this Agreement is
required to be made or taken on a day other than a business day, such payment
shall be made or action taken on the next business day following such day to
make such payment or do such act.

ARTICLE 2 – RESEARCH ANTIGENS

             2.1.       Designation of Research Antigens.

             Subject to the provisions of this Agreement, including
the availability of the Antigen pursuant to Section 2.3, EOS may acquire
Options pursuant to Section 4.1 for the following number of Research Antigens
during the term of the Research Program:

                           (a)         Upon
payment of the Initial Research Program Fee set forth in Section 3.4(a), EOS
may acquire Options for up to [*] ([*]) Research Antigens for evaluation in the
Research Program.

                           (b)        Upon
payment of the Second Research Program Fee set forth in Section 3.4(b), EOS may
acquire Options for up to an additional [*] ([*]) Research Antigens for
evaluation in the Research Program.

                           (c)         Upon
payment of the Third Research Program Fee set forth in Section 3.4(c), EOS may
acquire Options for up to an additional [*] ([*]) Research Antigens for
evaluation in the Research Program.

             EOS may acquire an Option for an Antigen by notifying
SGI of the identity of, and to the extent available the genetic sequence for,
the Antigen for which EOS wishes to acquire an Option.  Within [*] ([*])[*] following receipt of
such EOS notice, SGI will notify EOS whether the Option requested by EOS is available
pursuant to Section 2.3.

             Upon notice by SGI to EOS that an Option is available
for such Antigen pursuant to Section 2.3, such Antigen shall be deemed to be a
“Research Antigen” under this Agreement for the duration of the Option
Period.  Schedule C to this
Agreement will be amended from time to time to list the Research Antigens
(including a description thereof) under this Agreement.

             2.2.       Research License to EOS.

             Subject to the provisions of this Agreement, SGI hereby
grants to EOS and its Affiliates, for the term of the Research Program, an
exclusive license in the Territory under the SGI Technology solely for the
purpose of conducting research and development activities on the Research
Antigens and evaluating EOS’s interest to exercise the Options.  The research license granted to EOS under
this Section 2.2 shall not include (i) the right to use SGI
Technology for any commercial purpose whatsoever, (ii) the right to grant
sublicenses thereto to any Affiliate or Third-Party, (iii) the right to initiate
any human clinical trial in any country, or (iv) the right to make, have
made, use or sell a Product or the Drug Conjugation Technology for any purpose
other than the foregoing evaluation, including for any commercial purpose.

             2.3.       Availability of an Antigen.

             It is understood and agreed that SGI may be unable to
grant an Option or Exclusive License to an Antigen if, prior to EOS’s request
for an Option for such Antigen pursuant to Section 2.1, (i) [*] or (ii) [*]
EOS’s written request for an Option for the Antigen.

ARTICLE 3 - RESEARCH PROGRAM

             3.1.       Objective.  EOS intends to conduct a Research Program to evaluate Research
Antigens and Antibodies for commercial development under this Agreement.  In support of the Research Program, upon
receipt of Antibodies from EOS, SGI will prepare ADCs for EOS pursuant to
Section 3.5.

             3.2.       Conduct of Research Program.  EOS and SGI shall use all reasonable efforts
to complete research works in accordance with the stated objective of the
Research Program.  Any research work
performed by EOS and SGI pursuant hereto shall be performed in a good
scientific manner and in compliance with all applicable laws.

             3.3.       Term of the Research Program.  The initial term of the Research Program
shall be for a period of [*] ([*])[*] from the Effective Date (the “Initial
Research Program Term”), unless terminated earlier upon termination of this
Agreement in accordance with Article 15 hereof.  Subject to the written approval of SGI and to payment of the fee
by EOS to extend, as set forth in Section 3.4(d) below, the Research Program
will be extended for [*] ([*]) additional period of [*] ([*])[*] upon EOS’s
request by giving written notice to SGI not less than [*] ([*])[*] prior to the
expiration of the Initial Research Program Term (collectively with the Initial
Research Program Term, the “Research Program Term”).

             3.4.       Research Program Fees.  EOS shall pay to SGI the following amounts
in consideration of the Research Program:

                           (a)         Upon
execution and delivery of this Agreement by both Parties, EOS shall pay to SGI
a payment in the sum of [*] dollars ($[*]) by wire transfer of immediately
available funds, which payment shall be nonrefundable and non-creditable (the “Initial
Research Program Fee”).

                           (b)        If
EOS elects to [*] ([*]) [*] [*] ([*]) [*] pursuant to Section 2.1(b), EOS shall
pay a second payment in the sum of [*] Dollars ($[*]) by wire transfer of
immediately available funds, which payment shall be nonrefundable and
non-creditable (the “Second Research Program Fee”).

                           (c)         If
EOS elects to [*] ([*]) [*] ([*]) [*] pursuant to Section 2.1(c), EOS shall pay
a third payment in the sum of [*] Dollars ($[*]) by wire transfer of
immediately available funds, which payment shall be nonrefundable and
non-creditable (the “Third Research Program Fee”).

                           (d)        If
EOS and SGI agree to extend the Research Program for an additional [*] ([*])[*]
period pursuant to Section 3.3, EOS shall pay an additional payment in the sum
of [*] Dollars ($[*]) by wire transfer of immediately available funds, which
payment shall be nonrefundable [*].

             3.5.       SGI Preparation of ADCs.

             At the request of EOS during the Research Program Term,
SGI will use reasonable commercial efforts to prepare ADC’s for (i) [*]
and (ii) [*] [*] ([*]) [*].  The
terms and conditions applicable to SGI’s ADC preparation are set forth on Schedule D.  EOS shall pay SGI the amount set forth in Schedule D
within [*] ([*])[*] of receipt of an invoice from SGI for such amounts.  The Parties acknowledge and agree that SGI
will prepare [*].  If SGI is unable to
prepare an ADC within [*] ([*]) [*] following EOS’s delivery of the required
quantity of Antibody material (and if applicable, Control Antibody material),
EOS will have the option to designate a replacement Antibody to the same
Research Antigen (including a replacement Control Antibody, if applicable) at
any time during the Research Program Term and SGI will use reasonable
commercial efforts to prepare an ADC for such replacement Antibody (and
replacement Control Antibody, if applicable) for no additional charge.  EOS’s right to designate a replacement
Antibody (and replacement Control Antibody, if applicable) is EOS’s sole and
exclusive remedy for any failure by SGI to prepare any ADC contemplated by this
Section 3.5.

             EXCEPT AS MAY BE OTHERWISE PROVIDED IN ARTICLE 14, SGI
MAKES NO REPRESENTATIONS AND GRANTS NO WARRANTIES, EXPRESS OR IMPLIED, EITHER
IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, REGARDING THE ADC’S
PREPARED BY SGI INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS
FOR A PARTICULAR USE OR PURPOSE.

             3.6.       Confidentiality.  In order to facilitate the Research Program,
either Party may disclose confidential or proprietary information owned or
controlled by it to the other.  It is
hereby understood and agreed that such information shall be deemed “Confidential
Information” as defined in Article 10 and treated as such.

ARTICLE 4 – OPTIONS AND LICENSES

             4.1.       Option Grant.

                           4.1.1.    Grant
of the Options.  Subject to the
provisions of this Agreement, SGI hereby grants to EOS an exclusive Option for
each Research Antigen designated pursuant to Section 2.1 to obtain the
Exclusive License set forth in Section 4.2.1 during the Option Period.

                           4.1.2.    Exercise
of the Option.  At any time during
the Option Period with respect to a particular Research Antigen, EOS may
provide notice to SGI that it wishes to acquire an Exclusive License for the
SGI Technology solely for use with Products containing ADC’s directed against
the specified Research Antigen.  Upon
the exercise of each Option, EOS shall make a payment to SGI in the sum of [*]
Dollars ($[*]) by wire transfer of immediately available funds, which payment
shall be nonrefundable and non-creditable (the “Option Exercise Fee”).

                           4.1.3. Non-Exercise of the Option.  At the end of an Option Period for a
particular Research Antigen and in exchange for a payment to SGI in the sum of
$[*], EOS may be granted a [*] ([*])[*] extension of the Option Period for such
Research Antigen.  If by the end of an
Option Period (including its extension, as above) for any Research Antigen, EOS
has not exercised its Option, all rights related to the use of SGI Technology
in connection with the Antigen shall revert back to SGI.

             4.2.       Exclusive License Grant to EOS.

                           4.2.1.    Grant.  If (i) EOS elects to exercise its option to
acquire an Exclusive License with respect to a particular Research Antigen
pursuant to Section 4.1.2, and (ii) EOS pays the Option Exercise Fee pursuant
to Section 4.1.2, then subject to the terms and conditions of this Agreement,
and commencing as of the date that SGI has received the Option Exercise Fee
from EOS, SGI is automatically deemed to grant, and in such event hereby
grants, to EOS, on a Research Antigen-by-Research Antigen basis, a worldwide,
exclusive (even as to SGI), non-transferable, royalty-bearing license under the
SGI Technology, with the right to sublicense as permitted in Section 4.2.2, to
discover, have discovered, to develop, have developed, make, have made, import,
have imported, export, have exported, use, sell and have sold Products directed
toward such Research Antigen within the Field in the Territory (an “Exclusive
License”), whereupon the Research Antigen shall thereafter be deemed to be
an “Exclusive Antigen”.  EOS may
obtain an Exclusive License for each Research Antigen pursuant to this Section
4.2.1 until the expiration of the term of the Option Period for such Research
Antigen.  Upon expiration of the term of
the last Option Period hereunder, no further Exclusive Licenses shall be
granted under the terms of this Agreement.

                           The date upon which an Exclusive License
is granted with respect to each Research Antigen under this Section 4.2 is
referred to herein as the “Exclusive License Date” for such Research
Antigen.

                           4.2.2.    Rights to Sublicense.

                                        (a)         EOS shall have the right to sublicense
the rights granted to EOS pursuant to this Agreement to any Affiliate or any
Third-Party for any Exclusive Antigen or Product developed by EOS subject to
the terms and conditions of the SGI In-Licenses attached hereto as Schedule
E.

                                        (b)        [*] due to SGI by reason of completion of any milestones or
Net Sales of any Products by any such Sublicensee and its compliance with all
terms of this Agreement applicable to EOS (including all terms of this
Agreement identified as applicable to Sublicensee); and any such Sublicensee
agrees [*] (i) to keep books and records and permit SGI to review the
information concerning such books and records that EOS has in its possession in
accordance with the terms of this Agreement and (ii) to comply with all other
terms of this Agreement applicable to EOS (including all terms of this
Agreement identified as applicable to a Sublicensee).

                                        (c)         EOS shall notify SGI of each sublicense granted to
Affiliates or Third-Parties and shall provide SGI with the name and address of
each Sublicensee and a description of the rights granted and the territory
covered by each Sublicensee.

             4.3.       Improvements and New
Technologies.

                           4.3.1.    Improvements.  In the event that, during the Research
Program Term, SGI conceives, develops or reduces to practice an Improvement [*]
[*].

                           4.3.2.    New
Technologies.  Subject to the bona
fide rights of Third-Parties that may exist, [*].  SGI shall [*] under this Agreement; provided that [*].  For the purposes of clarity, the Parties
acknowledge and agree that EOS shall not [*]. 
Schedule B shall be amended from time to time to add the patents
and patent applications covering New Technologies and may be amended from time
to time to add any new patents or patent applications covering New Technologies
and Improvements related thereto and the specific terms of the SGI In-Licenses
covering such New Technologies and Improvements related thereto with which EOS
shall comply.

             4.4.       Compliance with the SGI In-Licenses.

                           4.4.1.    EOS,
its Affiliates and Sublicensees agree to comply with those covenants and
conditions of the SGI In-Licenses disclosed to EOS by SGI in advance and
attached hereto in Schedule E, as if they were a party to the SGI
In-Licenses.  The Parties agree that [*]
are Third-Party beneficiaries to this Agreement with respect to SGI Technology
that includes technology sublicensed under the [*] and/or the [*].

                           4.4.2.    SGI
will not enter into any amendment to an SGI In-License that imposes additional
obligations on EOS, or diminishes EOS’s rights, without the prior written
consent of EOS.  In the event of any
amendment or termination of any SGI In-License set forth on Schedule E
that relates to technology sublicensed to EOS under such SGI In-License, SGI shall notify EOS no
later than [*] ([*])[*] before the execution of any proposed amendment to or termination of
an SGI In-License. 
In the case of an amendment, such notification will include disclosure
of the material terms of the proposed amendment to an SGI In-License, including
all terms applicable to EOS.  [*].

                           4.4.3     SGI
will use commercially reasonable efforts to comply with, and exercise its
rights under, the SGI In-Licenses so as to ensure compliance by SGI of its
obligations under this Agreement.  [*].

ARTICLE 5 – TECHNOLOGY DISCLOSURE AND SUPPLY

             5.1.       Disclosure of Drug Conjugation Technology.

             SGI shall disclose to EOS such Drug Conjugation
Technology, SGI Know-How, New Technologies and Improvements as is necessary to
enable EOS to use the Drug Conjugation Technology, SGI Know-How, New
Technologies and Improvements at its own facilities on the terms and subject to
the conditions of this Agreement.  In
addition, during the term of this Agreement, SGI shall, upon EOS’s reasonable
request and with adequate notice to SGI, make available to EOS at SGI’s
facilities, SGI’s personnel to provide a reasonable amount of technical
assistance and training to EOS’s personnel. 
[*].

             5.2.       Identification of Technology.

             The Parties agree that all Drug Conjugation Technology,
SGI Know-How and Drug Conjugate Materials to be transferred to EOS pursuant to
this Agreement (“Transferred Technology, Know-How and Materials”) shall
be so transferred in the form of written memoranda marked confidential in the
case of such Technology and Know-How and, in the case of such Materials, by
clearly marked containers. When presented in this manner, these shall be deemed
to be “Confidential Information” in accordance with Section 10.1.  EOS will take reasonable and appropriate
measures to ensure that the confidentiality of all Transferred Technology,
Know-How and Materials is preserved and that the Transferred Technology,
Know-How and Materials are only used for the purposes authorized under the
Agreement and in compliance with this Agreement.  Failure by SGI to transfer such Transferred Technology,
Know-How and Materials in the manner contemplated in this Section 5.2 will
not be construed to limit the license granted to EOS under such SGI Technology
pursuant to Sections 2.2 or 4.2 hereof.

             5.3.       Supply of Drug Conjugate Materials.

             During the term of the Research Program and any
subsequent portion of the Option Period related to a specific Research Antigen,
SGI will provide reasonable quantities of Drug Conjugate Materials to EOS [*].

             If at any time during the term of this Agreement, [*].

             [*].

             [*].

             5.4.       Communication Among Parties.

             Each of EOS and SGI shall appoint a specific individual
who shall be available and shall act as a liaison person to facilitate the
day-to-day communications among the Parties. 
The names of the initial liaison persons who shall act on behalf of each
of the Parties shall be Richard Murray for EOS and Peter Senter for SGI.  Each of EOS and SGI agrees to notify the
other in accordance with the terms of Section 21.1 of this Agreement in the
event of a change in liaison person.

ARTICLE 6 - DEVELOPMENT AND COMMERCIALIZATION

             EOS shall use its commercially reasonable efforts and
diligence in developing and commercializing Product(s) related to Exclusive
Antigen(s) in accordance with its business, legal, medical and scientific
judgment, and in undertaking investigations and actions required to obtain
appropriate Regulatory Approval(s) necessary to market such Products that EOS
determines in its sole discretion to pursue in the Territory, such reasonable
efforts and diligence to be in accordance with the efforts and resources EOS
would use for product(s) owned by it or to which it has rights, which is of
similar market potential at a similar stage in development as the Products directed
towards the applicable Exclusive Antigen taking into account the
competitiveness of the marketplace, the proprietary position of the Product(s)
that EOS determines in its sole discretion to pursue, the relative potential
safety and efficacy of such Product(s), the regulatory requirements involved in
such Products’ development, commercialization and Regulatory Approval, the Cost
of Goods and availability of capacity to manufacture and supply such Product(s)
at commercial scale, the profitability of such Product(s), and other relevant
factors including technical, legal, scientific or medical factors.

             As to between the Parties, EOS shall be solely
responsible for funding all costs of the development and commercialization of
each Product EOS determines in its sole discretion to pursue.  EOS shall keep SGI informed in a timely
manner as to the progress of the development of Products EOS determines, from
time to time, to pursue.  Beginning on
[*] and thereafter within [*] ([*])[*] following the end of each calendar year,
EOS shall provide SGI with a written report summarizing EOS’s activities
related to research and development of Products and status of clinical trials
and government approvals necessary for marketing Products.  Beginning on [*] and thereafter within [*]
([*]) [*] following the end of each calendar year, SGI shall provide EOS with a
written report summarizing SGI’s activities related to preparing ADCs and
developing new Drug Conjugation Technology.

ARTICLE 7 – MAINTENANCE FEES, ROYALTIES AND MILESTONES.

             7.1.       Maintenance Fees

                           7.1.1.    EOS
shall pay to SGI an annual maintenance fee in the amount of [*] Dollars ($[*])
for each Exclusive Antigen [*] for each Exclusive Antigen.  [*]. 
SGI shall [*]: (a) [*] for a Product related to such Exclusive Antigen,
(b) [*] for a Product related to such Exclusive Antigen [*] ([*]) [*] of the
[*] for such Product, (c) the [*] for a Product related to such Exclusive
Antigen, and (d) the [*] of the [*] for a Product related to such Exclusive
Antigen.  Notwithstanding the foregoing,
[*]: (y) [*] Dollars ($[*]) if EOS [*] ([*]) [*] and (z) [*] Dollars ($[*]) if
EOS [*] ([*]) [*].

                           7.1.2.    EOS
may terminate the Exclusive License for any Exclusive Antigen for any reason
and at any time upon [*] ([*]) [*] prior notice to SGI, in which event no
maintenance fees shall accrue to SGI under Section 7.1.1 for such Research
Antigen following the termination date; provided that [*].  The Exclusive License for such Exclusive
Antigen shall terminate effective as of such termination date.  All rights related to the use of SGI
Technology in connection with the Exclusive Antigen shall revert back to SGI
after a waiting period of [*] ([*]) [*] after such termination date.

                           7.1.3.    Notwithstanding
anything to the contrary in this Section 7.1, EOS may reinstate the Exclusive
License for such former Exclusive Antigen within [*] ([*])[*] following the
termination date by notifying SGI and making an additional payment in the sum
of $[*] to SGI.

             7.2.       Royalties Payable by EOS.

             In consideration for the Exclusive Licenses granted to
EOS herein, during the Royalty Term, EOS shall pay to SGI royalties on Net
Sales of Products.  Such royalties shall
be established at the following rates, determined on a Product-by-Product
basis:

	 	(a)	[*]%
  of the first [*] Dollars ($[*]) in aggregate Net Sales of the Product in each
  calendar year;
	 	 	 
	 	(b)	[*]%
  of incremental aggregate Net Sales of the Product up to [*] Dollars ($[*]) in
  each calendar year; and
	 	 	 
	 	(c)	[*]%
  of incremental aggregate Net Sales of the Product in excess of [*] Dollars
  ($[*]) in each calendar year.

             7.3.       Third-Party Royalties.

                           7.3.1.    EOS
shall pay any Third-Party royalties owed on account of its sales of Product in
the Licensed Territory, including royalties owed due to use of the SGI
Technology; [*].  All current
Third-Party royalties known to SGI are set forth on Schedule B and the
terms of such royalties have been disclosed to EOS and are set forth in Schedule
E.

	 	7.3.2.	[*]:
	 	 	 
	 	(a)	[*];
	 	 	 
	 	(b)	[*];
  and
	 	 	 
	 	(c)	[*].

             7.4.       Non-Royalty Sales.

             No royalty shall be payable under this Article 7
with respect to sales of Products among EOS and its Affiliates or its
Sublicensees or among Sublicensees and their Affiliates, but a royalty shall be
due upon the subsequent sale of the Product to a Third-Party.

             7.5.       Milestone Payments.

             As additional consideration for the licenses, rights and
privileges granted to it hereunder, EOS shall pay to SGI the following
milestone payments to SGI within [*] ([*])[*] of the first occurrence of each
event set forth below with respect to Products, whether such events are
achieved by EOS, its Affiliates or Sublicensees:

                           (a)         Upon
[*] for each Product, [*] Dollars ($[*]);

                           (b)        Upon
[*] for each Product, [*] Dollars ($[*]);

                           (c)         Upon
[*] for each Product, [*] Dollars ($[*]);

                           (d)        Upon
[*] for each Product in either the [*] (each, a “Major Market”), [*]
Dollars ($[*]);

                           (e)         Upon
[*] for each Licensed Product in a second Major Market, [*] Dollars ($[*]); and

                           (f)         Upon
[*], said indication to be the result of an [*] for each Product in a Major
Market, [*] Dollars ($[*]).

             EOS will only be required to pay each of the above
milestones (other than the milestone set forth in Section 7.5(f)) to SGI for
the [*] Product for each Exclusive Antigen to complete the milestone
event.  EOS will only be required to pay
the milestone set forth in Section 7.5(f) to SGI for the [*] Product for each
Exclusive Antigen that completes such milestone event.

ARTICLE 8 - ROYALTY REPORTS AND ACCOUNTING

             8.1.       Reports, Exchange Rates.

                           8.1.1.    During
the term of this Agreement following the First Commercial Sale and during the
Royalty Term, EOS shall furnish to SGI, with respect to each Calendar Quarter,
a written report showing on a consolidated basis in reasonably specific detail
and on a country-by-country basis, (a) the gross sales of Products sold by
EOS, its Affiliates and its Sublicensees in the Territory during the
corresponding Calendar Quarter and the calculation of Net Sales from such gross
sales; (b) the royalties payable in US dollars, if any, which shall have
accrued hereunder based upon Net Sales of Products; (c) the withholding
taxes, if any, required by law to be deducted in respect of such royalties;
(d) the dates of the First Commercial Sale of each Product in each country
in the Territory if it has occurred during the corresponding Calendar Quarter;
and (e) the exchange rates (as determined pursuant to Section 8.1.4
herein) used in determining the royalty amount expressed in US dollars
(collectively, “Reports”).

                           8.1.2.    EOS
shall include in each permitted sublicense granted by it pursuant to this
Agreement a provision requiring its Sublicensees to make Reports to EOS within
[*] ([*])[*] of the close of each Calendar Quarter, to keep and maintain
records of sales made pursuant to such sublicense and to grant access to such
Reports by SGI’s independent accountant to the same extent required with
respect to EOS’s Reports under this Agreement.

                           8.1.3.    Reports
shall be due on the [*] ([*]) [*] following the close of each Calendar
Quarter.  EOS shall keep complete and
accurate records in sufficient detail to properly reflect all gross sales and
Net Sales and to enable the royalties payable hereunder to be determined.

                           8.1.4.    With
respect to sales (if any) of Products invoiced in US dollars, the gross sales,
Net Sales, and royalties payable shall be expressed in US dollars.  With respect to sales of Products invoiced
in a currency other than US dollars, the gross sales, Net Sales and royalties
payable shall be expressed in the currency of the invoice issued by the Party
making the sale together with the US dollars equivalent of the royalty payable,
calculated using the following rates: (i) [*], or (ii) [*].

             8.2.       Audits.

                           8.2.1.    Upon
the written request of SGI and not more than once in each calendar year, EOS
shall permit an independent certified public accounting firm of internationally
recognized standing, selected by SGI and reasonably acceptable to EOS, at SGI’s
expense, to have access during normal business hours to such of the records of
EOS and its Affiliates as may be reasonably necessary to verify the accuracy of
the Reports hereunder for any year ending not more than [*] ([*]) [*] prior to
the date of such request.  The
accounting firm shall disclose to SGI only whether the records are correct or
not and the specific details concerning any discrepancies.  No other information shall be shared.

                           8.2.2.    If
such accounting firm concludes that additional royalties were owed during such
period, EOS shall pay the additional royalties within [*] ([*])[*] of the date
SGI delivers to EOS such accounting firm’s written report so concluding.  The fees charged by such accounting firm
shall be paid by SGI; provided, however, if the audit discloses
that the royalties payable by EOS for the audited period are more than [*]
percent ([*]%) of the royalties actually paid for such period, then EOS shall
pay the reasonable fees and expenses charged by such accounting firm.

                           8.2.3.    Upon
the expiration of [*] ([*])[*] following the end of any calendar year, the
calculation of royalties payable with respect to such year shall be binding and
conclusive upon SGI, and EOS, its Affiliates and Sublicensees shall be released
from any liability or accountability with respect to royalties for such year.

             8.3.       Confidential Financial Information.

             SGI shall treat all financial information subject to
review under this Article 8 or under any sublicense agreement as Confidential
Information of EOS, and shall cause its accounting firm to retain all such
financial information in confidence.

ARTICLE 9 - PAYMENTS. 
LATE PAYMENTS

             9.1.       Payment Terms.

             Royalties shown to have accrued by each Report provided
for under Article 8 of this Agreement shall be due on the date such Report is
due.  Payment of royalties in whole or
in part may be made in advance of such due date.  Past due payments shall accrue interest at a rate of [*] percent
([*]%) per annum, or the maximum applicable rate permitted by law, unless
occurring as a result of an event the Parties agree constitutes an Event of
Force Majeure or as a result of a good faith dispute between the Parties
regarding performance or breach of their obligations hereunder.

             9.2.       Payment Method.

             All payments by EOS to SGI under this Agreement shall be
paid in US dollars, and all such payments shall be made by bank wire transfer
in immediately available funds to the bank account designated by SGI in
writing.

             9.3.       Exchange Control.

             If at any time legal restrictions prevent the prompt
remittance of part or all royalties with respect to any country in the
Territory where Product is sold, payment shall be made through such lawful
means or method as the Parties reasonably shall determine.

             9.4.       Withholding Taxes.

             Except as otherwise provided below, all amounts owing from
EOS to SGI under this Agreement are gross amounts.  EOS shall be entitled to deduct the amount of any withholding
taxes payable or required to be withheld by EOS, its Affiliates or
Sublicensees, to the extent EOS, its Affiliates or Sublicensees pay to the
appropriate governmental authority on behalf of SGI such taxes.  EOS shall use commercially reasonable
efforts to minimize any such taxes, levies or charges required to be withheld
on behalf of SGI by EOS, its Affiliates or Sublicensees.  EOS promptly shall deliver to SGI proof of
payment of all such taxes, levies and other charges, together with copies of
all communications from or with such governmental authority with respect
thereto.

ARTICLE 10 - CONFIDENTIALITY

             10.1.     Non-Disclosure Obligations.

             Except as otherwise provided in this Article 10, during
the Term and for a period of [*] ([*]) [*] thereafter, each Party shall
maintain in confidence, and use only for purposes as expressly authorized and
contemplated by this Agreement, all confidential or proprietary information,
data, documents or other materials supplied by the other Party under this
Agreement and marked or otherwise identified as “Confidential,”
including SGI Know-How, Drug Conjugation Technology, Improvements and New
Technologies.  For purposes of this
Agreement, information and data described above shall be hereinafter referred
to as “Confidential Information.” 
Each Party shall use at least the same standard of care as it uses to
protect its own Confidential Information to ensure that its and its Affiliates’
employees, agents, consultants and clinical investigators only make use of
Confidential Information for purposes as expressly authorized and contemplated
by this Agreement and do not disclose or make any unauthorized use of such Confidential
Information.

             10.2.     Permitted Disclosures.

             Notwithstanding the foregoing, the provisions of Section
10.1 hereof shall not apply to information, documents or materials that the
disclosing Party can conclusively establish:

                           (a)         have
become published or otherwise entered the public domain other than by acts of
the disclosing Party or its Affiliates in contravention of this Agreement;

                           (b)        are
permitted to be disclosed by prior consent of the other Party;

                           (c)         have
become known to the disclosing Party by a Third-Party, provided such
Confidential Information was not obtained by such Third-Party directly or
indirectly from the other Party under this Agreement on a confidential basis;

                           (d)        prior
to disclosure under the Agreement, was already in the possession of the
disclosing Party, its Affiliates or Sublicensees, provided such Confidential
Information was not obtained directly or indirectly from the other Party under
this Agreement;

                           (e)         is
disclosed in a press release agreed to by both Parties hereto, which agreement
shall not be unreasonably withheld; and

                           (f)         are
required to be disclosed by the disclosing Party to comply with any applicable
law, regulation or court order, or are reasonably necessary to obtain patents,
copyrights or authorizations to conduct clinical trials with, and to
commercially market Product(s), provided that the disclosing Party shall
provide prior notice of such disclosure to the other Party and take reasonable
and lawful actions to avoid or minimize the degree of disclosure.

             10.3.     Terms of the Agreement.

             EOS and SGI shall not disclose any terms or conditions
of this Agreement to any Third-Party without the prior consent of the other
Party, except as required by applicable laws, regulations or a court order (and
in any such case the disclosing Party shall provide notice to the other Party
and takes reasonable and lawful actions to avoid or minimize the degree of such
disclosures).

             10.4.     Press Releases and Other Disclosures to Third-Parties.

             Neither SGI nor EOS will, without the prior consent of
the other, issue any press release or make any other public announcement or
furnish any statement to any Person (other than either Parties’ respective
Affiliates) concerning the existence of this Agreement, its terms and the transactions
contemplated thereby, except for (i) general statement referring to the
existence of this Agreement, and identity of the Parties but no other details,
(ii) disclosures made in compliance with Sections 10.2 and 10.3 hereof,
(iii) attorneys, consultants, and accountants retained to represent them
in connection with the transactions contemplated hereby and
(iv) occasional, brief comments by the respective officers of EOS and SGI
consistent with such guidelines for public statements as may be mutually agreed
by EOS and SGI made in connection with routine interviews with analysts or
members of the financial press.

             10.5.     Publications Regarding Results of the Research Program.

             No Party may publish, present or announce results of the
Research Program either orally or in writing (the “Publication”) without
obtaining the written consent of the other Party.  The other Party shall have [*] ([*]) [*] from receipt of the
proposed Publication to provide comments and/or proposed changes to the
disclosing Party.  The disclosing Party
shall take into account the comments and/or proposed changes made by the other
Party on any Publication and shall agree to have employees or others acting on
behalf of the other Party be mentioned as co-authors on any Publication describing
results to which such persons have contributed.  If the other Party reasonably determines the Publication would
amount to the public disclosure of such Party’s Confidential Information and/or
of a patentable invention upon which a patent application should be filed prior
to any such disclosure, submission of the concerned Publication to
Third-Parties shall be delayed for a [*] ([*])[*] period from the date of said
notice, or for such longer period which may appear necessary for appropriately
deleting Confidential Information from the proposed Publication and/or drafting
and filing a patent application covering such invention.

ARTICLE 11 - INVENTIONS AND PATENTS

             11.1.     Ownership of Inventions.

                           11.1.1.  Inventorship.  Subject to the terms of this Article 11, inventorship of any
inventions arising out of the Research Program or under this Agreement shall be
determined according to U.S. law. Any inventions or other intellectual property
invented solely by one Party shall be owned by that Party.

                           11.1.2.  Ownership of SGI Technology and Jointly-Invented
Inventions Related Thereto.

                           All right, title and interest to the SGI
Technology shall (subject to any licenses explicitly granted hereunder) at all
times remain with and be vested in SGI. 
Any invention or other intellectual property made, and data derived, by
jointly EOS or its respective employees, consultants or agents and SGI or its
respective employees, consultants or agents that relate to the SGI Technology
shall be owned [*].  EOS shall promptly
notify SGI of any such invention or other intellectual property, and cooperate
with SGI at SGI’s request and expense, in the preparation, filing, prosecution,
and defense of patent applications and patents relating thereto.  Subject to the terms of this Article 11, [*]
that relate to the SGI Technology, and shall in a reasonably timely manner
execute those documents, as requested by SGI, necessary to document and/or
perfect the assignment of such inventions and intellectual property.

                           11.1.3.  Ownership of Antibodies, Research Antigens, Exclusive
Antigens,and Jointly-Invented Inventions Related Thereto.  Subject to Section 11.1.2, all right, title
and interest to the Antibodies, Research Antigens and Exclusive Antigens shall
at all times remain with and be vested in EOS. 
Any invention or other intellectual property made, and data derived, by
jointly SGI or its respective employees, consultants or agents and EOS or its
respective employees, consultants or agents that relate to the Antibodies, the
Research Antigens, the Exclusive Antigens or any Antibody included in the ADC,
shall be owned [*].  SGI shall promptly
notify EOS of any such invention or other intellectual property, and cooperate
with EOS at EOS’s request and expense, in the preparation, filing, prosecution,
and defense of patent applications and patents relating thereto.  Subject to the terms of this Article 11, [*]
that relate to the above noted technology as well as any invention or other
intellectual property made, and data derived as it directly relates, and only
insofar as it directly relates, to an ADC licensed under this Agreement
regardless of inventorship, and shall in a reasonably timely manner execute
those documents, as requested by EOS, necessary to document and/or perfect the
assignment of such inventions and intellectual property.

             11.2.     Patent Prosecution and
Maintenance.

                           11.2.1.  SGI
shall be responsible for and shall control the preparation, filing,
prosecution, grant and maintenance of all Licensed Patents.  SGI shall, at its sole expense, prepare,
file, prosecute and maintain such Licensed Patents in good faith consistent
with its customary patent policy and its reasonable business judgment, and
shall consider in good faith the interests of EOS in so doing.

                           11.2.2.  Subject
to Section 11.2.1, EOS shall be responsible for and shall control the
preparation, filing, prosecution, grant and maintenance, of any patents and
patent applications having as subject matter an ADC, Antibody, Research Antigen
or Exclusive Antigen Invention (the “EOS Patents”). EOS shall have the
right, but not the obligation, at its sole discretion and expense, prepare,
file, prosecute and maintain such patent rights in good faith consistent with
its customary patent policy and its reasonable business judgment.

                           11.2.3.  The
Parties shall at all times fully cooperate in order to reasonably implement the
foregoing provisions.

             11.3.     Enforcement of Licensed Patents.

                           11.3.1.  SGI
shall have the obligation in Major Markets and the right in all other markets,
at its sole expense, to determine the appropriate course of action to enforce
the Licensed Patents or otherwise abate the infringement thereof, to take (or
refrain from taking) appropriate action to enforce the Licensed Patents, to
control any litigation or other enforcement action and to enter into, or
permit, the settlement of any such litigation or other enforcement action with
respect to the Licensed Patents, and in good faith shall consider the interests
of EOS in so doing; provided that nothing herein shall be construed to obligate
SGI to take any action that would be commercially unreasonable or would subject
SGI to undue business risk.  All monies
recovered upon the final judgment or settlement of any such suit to enforce any
Licensed Patents shall be retained by SGI. 
EOS and SGI shall fully cooperate with each other in any action to
enforce the Licensed Patents.  If SGI
fails to take any action to enforce the Licensed Patents or control any
litigation with respect to the licensed Patents within a period of [*] ([*])[*]
after reasonable notice of the infringement of the Licensed Patents, then EOS
shall have the right to bring and control any such action by counsel of its own
choice, and in such case, all monies recovered upon the final judgment or
settlement of any such suit to enforce any Licensed Patents shall be retained
by EOS.  In such a case, SGI shall
cooperate fully with EOS, at EOS’s expense, in its efforts to enforce the
Licensed Patents, including being joined as a party to such action if
necessary.

                           11.3.2.  EOS
shall have the right, at its sole expense, to determine the appropriate course
of action to enforce the EOS Patents or otherwise abate the infringement
thereof, to take (or refrain from taking) appropriate action to enforce the EOS
Patents, to control any litigation or other enforcement action and to enter
into, or permit, the settlement of any such litigation or other enforcement
action with respect to the EOS Patents. 
All monies recovered upon the final judgment or settlement of any such
suit to enforce any EOS Patents shall be retained by EOS.  SGI and EOS shall fully cooperate with each
other in any action to enforce the EOS Patents.

             11.4.     Prior Patent Rights.  Notwithstanding anything to the contrary in
this Agreement, with respect to any Licensed Patents that are subject to the
SGI In-Licenses, the rights and obligations of the Parties under Section 11.2
and 11.3 shall be subject to SGI’s licensees’ rights to participate in and
control prosecution, maintenance and enforcement of such Licensed Patents in
accordance with the terms and conditions of the applicable SGI In-License.

ARTICLE 12 - INFRINGEMENT ACTIONS BY THIRD-PARTIES

             If EOS, SGI or their respective Affiliates, or EOS’s
Sublicensees, is sued by a Third-Party for infringement of a Third-Party’s
patent because of the use of the Drug Conjugation Technology, the Party which
has been sued shall promptly notify the other Party no event later than [*]
([*])[*] of the institution of such suit. 
The notice shall set forth the facts of such infringement and provide
evidence of such infringement that is within the notifying Party’s
control.  SGI shall have the right, in
its sole discretion, to control the defense of such suit at its own expense, in
which event EOS shall have the right to be represented by advisory counsel of
its own selection, at its own expense, and shall cooperate fully in the defense
of such suit and furnish to SGI all evidence and assistance in its
control.  If SGI does not elect within
[*] ([*])[*] after receipt of such notice to so control the defense of such
suit, EOS may undertake such control at its own expense, and SGI shall then
have the right to be represented by advisory counsel of its own selection and
at its own expense, and SGI shall cooperate fully in the defense of such suit
and furnish to EOS all evidence and assistance in SGI’s control.  The Party controlling the suit shall keep
the other Party reasonably informed of the status of the suit under this
Article 12.  In no event may the Party
controlling the suit settle or otherwise consent to an adverse judgment in such
suit that diminishes the rights or interests of the non-controlling Party
without the express written consent of the non-controlling Party.  Any judgments, awards, settlements or
damages payable with respect to legal proceedings covered by this Article 12
shall be paid by or to the Party which controls the litigation; provided,
however, that if the other Party has elected to be represented by
advisory counsel, the other Party shall receive the actual reasonable cost of
its legal fees for such advisory counsel.

ARTICLE 13 - REGULATORY ASSISTANCE

             Should EOS develop an ADC for clinical development, SGI
will provide to a reasonable extent, at EOS’s request, technical information
required for EOS to file for and obtain permission to commence human clinical
trials.  This information will include,
as available, Chemistry Manufacturing and Controls documentation, other
toxicity and safety data, access to any drug master files on record with the
FDA and any other relevant materials. 
EOS shall reimburse SGI for any out-of-pocket costs incurred by SGI in
providing such information plus an amount equal to SGI’s fully burdened FTE
rate, which rate shall not exceed $[*] per year.

ARTICLE 14 – REPRESENTATIONS AND WARRANTIES

             14.1.     Representations and Warranties.

                           (a)         This
Agreement has been duly executed and delivered by each Party and constitutes
the valid and binding obligation of each Party, enforceable against such Party
in accordance with its terms, except as enforceability may be limited by
bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium or
other laws relating to or affecting creditors’ rights generally and by general
equitable principals.  The execution,
delivery and performance of this Agreement has been duly authorized by all
necessary action on the part of each Party, its officers and directors.

                           (b)        The
execution, delivery and performance of the Agreement by each Party does not
conflict with any agreement, instrument or understanding, oral or written, to
which it is a party or by which it is bound, nor violate any law or regulation
of any court, governmental body or administrative or other agency having
jurisdiction over it.

                           (c)         SGI
has not, and during the term of the Agreement will not, grant any right to any
Third-Party relating to the Licensed Patents and SGI Know-how which would
conflict with the rights granted to EOS hereunder.

                           (d)        SGI
represents and warrants that it has the right to grant the licenses granted
herein and that it has no knowledge of any rights of any Third-Parties that
would interfere with the practice of the Licensed Patents or other SGI
Technology.

                           (e)         SGI
represents and warrants that all Drug Conjugate Materials manufactured under
SGI’s authority will be in conformity with the agreed upon specifications upon
delivery to EOS.

             14.2.     Performance by Affiliates.

             The Parties recognize that each may perform some or all
of its obligations under this Agreement through Affiliates, provided, however,
that each Party shall remain responsible and be guarantor of the performance by
its Affiliates and shall cause its Affiliates to comply with the provisions of
this Agreement in connection with such performance.

ARTICLE 15 – TERM AND TERMINATION

             15.1.     Term

             Unless earlier terminated pursuant to this Article 15,
the term of this Agreement shall commence on the Effective Date and shall
remain in full force and effect until the earlier of (i) the expiration of the
last to expire Option Period unless EOS exercises at least [*] ([*]) Option
prior to such date; or (ii) the expiration of the last to expire Royalty Term.

             15.2.     Termination by EOS.

             EOS shall have the right, at any time in its sole
discretion, to terminate this Agreement as a whole, either forthwith upon
written notice to SGI if such notice is sent before the end of the Research
Program Term, or by providing not less than [*] ([*]) [*] prior notice to SGI
of such termination; provided, however if EOS elects to terminate
this Agreement as a result of an amendment to an SGI In-License as set forth in
Section 7.3.1, EOS shall have to provide only [*] ([*])[*] prior notice to SGI
of such termination.

             15.3.     Discontinuance of Development Efforts by EOS.

             EOS shall promptly give SGI notice if EOS intends to
abandon permanently the commercial development of any Exclusive Antigen
whereupon any Exclusive License with respect to such Exclusive Antigen shall
automatically terminate and all rights related to the use of SGI Technology in
connection with the Exclusive Antigen shall revert back to SGI.

             15.4.     Termination for Cause.

             Either Party may terminate this Agreement for material
breach by the other Party (the “Breaching Party”) of any material
provision of the Agreement, if the Breaching Party has not cured such breach within
[*] ([*])[*] after notice thereof; provided, however, that
neither Party shall be deemed to be in material breach of this Agreement for
purposes of a termination hereunder during any period in which a good faith
dispute between the Parties exists regarding performance of breach of its
obligations hereunder, and provided further, however, that in the event EOS
fails to timely pay SGI the annual maintenance fees, royalty payments and
milestone payments set forth in Article 7, the Research Program Fee(s) set
forth in Section 3.4 or the Option Exercise Fee(s) set forth in
Section 4.1.2, EOS shall have only [*] ([*])[*] to cure such material
breach.

             15.5.     Termination Upon Insolvency.

             Either
Party may terminate this Agreement if, at any time, the other Party shall file
in any court or agency pursuant to any statute or regulation of any state,
country or jurisdiction, a petition in bankruptcy or insolvency or for
reorganization or for an arrangement or for the appointment of a receiver or
trustee of that Party or of its assets, or if such other Party proposes a
written agreement of composition or extension of its debts, or if such other
Party shall be served with an involuntary petition against it, filed in any
insolvency proceeding, and such petition shall not be dismissed within [*]
([*])[*] after the filing thereof, or if such other Party shall propose or be a
party to any dissolution or liquidation, or if such other Party shall make an
assignment for the benefit of its creditors.

             15.6.     Termination of SGI In-Licenses.  All rights and obligations under an SGI
In-License sublicensed under this Agreement shall terminate upon [*] ([*])[*]
prior written notice by SGI if EOS breaches any material provision of such SGI
In-License Agreement and fails to cure such breach within such [*]  ([*]) [*] period; provided, however such
cure period may be extended by consent of the Parties.  All rights and obligations under the [*]
shall automatically terminate if EOS fails to maintain the insurance required
under the [*].  All rights and
obligations under an SGI In-License sublicensed under this Agreement shall
terminate upon termination of such SGI In-License; subject to EOS’s right, if
any, under such SGI In-License to enter into a direct license with licensor
upon the terms and conditions set forth in such SGI In-License.

             15.7.     Effect of Expiration and Termination.

                           15.7.1. 
Except where explicitly provided within this Agreement, termination of this
Agreement for any reason, or expiration of this Agreement, with not affect any:
(i) obligations, including payment of any royalties or other sums which have
accrued as of the date of termination or expiration, and (ii) rights and
obligations which, from the context thereof, are intended to survive
termination or expiration of this Agreement, including provisions of
Articles 10, 11, 12, 16 and 22, and Sections 8.2, 8.3 and 15.7, which
shall survive the expiration or termination of the Agreement.  Notwithstanding the foregoing, all licenses
granted by SGI to EOS hereunder, including all Exclusive Licenses, will
immediately terminate upon termination of this Agreement pursuant to Section
15.2 or Section 15.4 or Section 15.5.

                           15.7.2. 
Upon the expiration of the Royalty Term for each Exclusive Antigen pursuant to
Section 15.1, SGI shall grant EOS a royalty-free, perpetual, worldwide, license
to use the SGI Technology for that Exclusive Antigen.

ARTICLE 16 - INDEMNITY.

             16.1.     Direct Indemnity.

                           16.1.1. 
Each Party shall indemnify and hold harmless, and hereby forever releases and
discharges the other Party from and against all claims, demands, liabilities,
damages and expenses, including attorneys’ fees and costs (collectively, the “Liabilities”)
arising out of (i) the breach of any material provision of this Agreement by
the indemnifying Party (or the inaccuracy of any representation or warranty
made by such Party in this Agreement), except to the extent such Liabilities
resulted from the gross negligence, recklessness or willful misconduct of the
other Party; or (ii) the gross negligence, recklessness or willful misconduct
of the indemnifying Party.

                           16.1.2. 
EOS shall indemnify and hold harmless, and hereby forever releases and
discharges SGI from and against all Liabilities suffered or incurred arising
out of any Third-Party claims for personal injury, death or disability or any
product recall to the extent caused by (a) any failure to test for or provide
adequate warnings of adverse side effects to the extent such failure arises out
of acts or omissions in connection with the preclinical or clinical testing of
any Product, (b) any manufacturing defect in any Product or (c) any other act
or omission of EOS in connection with its obligations under this Agreement;
except in each case to the extent such Liabilities resulted from the gross
negligence, recklessness or willful misconduct by SGI or the inaccuracy of any
representation or warranty made by SGI in this Agreement.

                           16.1.3. 
SGI shall indemnify and hold harmless, and hereby forever releases and
discharges EOS from and against all Liabilities suffered or incurred arising
out of any Third-Party claims for personal injury, death or disability or any
product recall to the extent caused by (a) any SGI Technology incorporated in a
product other than an EOS Product, (b) any manufacturing defect in any SGI
Technology, or (c) any other act or omission of SGI in connection with its
obligations under this Agreement; except in each case to the extent such
Liabilities resulted from the gross negligence, recklessness or willful
misconduct by EOS or the inaccuracy of any representation or warranty made by
EOS in this Agreement.

             16.2.     Procedure.

             A Party (the “Indemnitee”) that intends to claim
indemnification under this Article 16 shall promptly provide notice to the
other Party (the “Indemnitor”) of any Liability or action in respect of
which the Indemnitee intends to claim such indemnification, which notice shall
include a reasonable identification of the alleged facts giving rise to such
Liability, and the Indemnitor shall have the right to participate in, and, to
the extent the Indemnitor so desires, jointly with any other Indemnitor
similarly noticed, to assume the defense thereof with counsel selected by the
Indemnitor; provided, however, that the Indemnitee shall have the
right to retain its own counsel, with the fees and expenses to be paid by the
Indemnitor, if representation of such Indemnitee by the counsel retained by the
Indemnitor would be inappropriate due to actual or potential differing
interests between such Indemnitee and any other Party represented by such
counsel in such proceedings.  Any
settlement of a Liability for which any Indemnitee seeks to be reimbursed,
indemnified, defended or held harmless under this Article 16 shall be subject
to prior consent of such Indemnitee, such consent shall be withheld
unreasonably

ARTICLE 17- FORCE MAJEURE

             No Party (or any of its Affiliates) shall be held liable
or responsible to the other Party (or any of its Affiliates) nor be deemed to
have defaulted under or breached the Agreement for failure or delay in
fulfilling or performing any term of the Agreement when such failure or delay
is caused by or results from causes beyond the reasonable control of the
affected Party (or any of its Affiliates) including fire, floods, embargoes,
war, acts of war (whether war be declared or not), insurrections, riots, civil
commotions, acts of God or acts, or omissions or delays in acting by any
governmental authority (collectively, “Events of Force Majeure”); provided,
however, that the affected Party shall exert all reasonable efforts to
eliminate, cure or overcome any such Event of Force Majeure and to resume
performance of its covenants with all possible speed.  Notwithstanding the foregoing, to the extent that an Event of
Force Majeure continues for a period in excess of six (6) months, the affected
Party shall promptly notify in writing the other Party of such Event of Force
Majeure and within four (4) months of the other Party’s receipt of such notice,
the Parties agree to negotiate in good faith either (i) to resolve the Event of
Force Majeure, if possible, (ii) to extend by mutual agreement the time period
to resolve, eliminate, cure or overcome such Event of Force Majeure, (iii) to
amend this Agreement to the extent reasonably possible, or (iv) to terminate
this Agreement.

ARTICLE 18 - ASSIGNMENT

             This Agreement may not be assigned or otherwise
transferred, nor, except as expressly provided hereunder, may any right or
obligations hereunder be assigned or transferred to any Third-Party by either
Party without the consent of the other Party, such consent not to be
unreasonably withheld; provided, however, that either Party may,
without such consent but with notification, assign this Agreement and its
rights and obligations hereunder to any of its Affiliates or in connection with
the transfer or sale of all or substantially all of its business, or in the
event of its merger or consolidation (such merger or consolidation shall be
hereinafter referred to as a “Change in Control”).  Any permitted assignee shall assume all
rights and obligations of its assignor under this Agreement; provided, however,
that an acquiror of SGI in connection with a Change of Control shall not be
obligated, but shall have the right, to disclose or offer to EOS pursuant to
Section 4.3 any Improvements or New Technologies owned or controlled by such
acquiror prior to the Change of Control, or any Improvements or New
Technologies owned or controlled by acquiror or SGI after a Change of Control;
provided, however, to the extent that SGI continues to exist as a separate
entity, Improvements derived from the SGI Technology will continue to be
subject to the terms and conditions of this Agreement.

ARTICLE
19 - SEVERABILITY

             Each Party hereby agrees that it does not intend to
violate any public policy, statutory or common laws, rules, regulations, treaty
or decision of any government agency or executive body thereof of any country
or community or association of countries. 
Should one or more provisions of this Agreement be or become invalid, the
Parties hereto shall substitute, by mutual consent, valid provisions for such
invalid provisions which valid provisions in their economic effect are
sufficiently similar to the invalid provisions that it can be reasonably
assumed that the Parties would have entered into this Agreement with such
provisions.

             In case such provisions cannot be agreed upon, the
invalidity of one or several provisions of this Agreement shall not affect the
validity of this Agreement as a whole, unless the invalid provisions are of
such essential importance to this Agreement that it is to be reasonably assumed
that the Parties would not have entered into this Agreement without the invalid
provisions.

ARTICLE 20 – INSURANCE

             During the term of this Agreement and thereafter for the
period of time required below, each Party shall maintain an [*] insurance in
the [*] and [*] and [*]; and commencing not later than [*] of the [*] and
thereafter for the [*], EOS shall [*] on an ongoing basis [*] in the [*] and
[*].  All of such [*] shall be
maintained [*] and an [*].

             [*] than the [*] of [*] with respect to the [*], and not
later than [*], EOS shall [*] to [*] a [*]. 
Thereafter EOS shall [*] and [*].

             EOS [*] shall [*] on [*] hereunder and shall [*] that
[*] shall [*] of [*] in the [*].

ARTICLE 21 – EXCLUSIVITY

             [*].

ARTICLE 22 - MISCELLANEOUS

             22.1.     Notices.

             Any consent, notice or report required or permitted to
be given or made under this Agreement by one of the Parties hereto to the other
shall be in writing, delivered personally or by facsimile (and promptly
confirmed by personal delivery, first class air mail or courier), first class
air mail or courier, postage prepaid (where applicable), addressed to such
other Party at its address indicated below, or to such other address as the
addressee shall have last furnished in writing to the address or in accordance
with this Section 22.1 and (except as otherwise provided in this Agreement)
shall be effective upon receipt by the addressee.

If
to Seattle Genetics:

22215 26th Avenue SE

Suite 3000

Bothell, WA 98021

Attention:  Chief Executive Officer

With
copy to:

Venture Law Group

4750 Carillon Point

Kirkland, WA  98033

Attention: Sonya F. Erickson

If
to EOS Biotechnology:

225A Gateway Blvd

S. San Francisco, CA 94080

Attention:  Chief Executive Officer

With
copy to:

Morgan, Lewis & Bockius LLP

1701 Market Street

Philadelphia, PA 19103

Attention:  Manya S. Deehr

             22.2.     Applicable Law.

             The Agreement shall be governed by and construed in
accordance with the laws of the State of Washington, without regard to the
conflict of law principles thereof.

             22.3.     Dispute Resolution.

             The Parties agree that if any dispute or disagreement
arises between EOS on the one hand and SGI on the other in respect of this
Agreement, they shall follow the following procedure in an attempt to resolve
the dispute or disagreement.

                           (a)         The
Party claiming that such a dispute exists shall give notice in writing (“Notice
of Dispute”) to the other Party of the nature of the dispute;

                           (b)        Within
[*] ([*])[*] of receipt of a Notice of Dispute, a nominee or nominees of EOS
and a nominee or nominees of SGI shall meet in person and exchange written
summaries reflecting, in reasonable detail, the nature and extent of the
dispute, and at this meeting they shall use their reasonable endeavors to
resolve the dispute;

                           (c)         If,
within a further period of [*] ([*])[*], the dispute has not been resolved, the
President of SGI and the President of EOS shall meet at a mutually agreed upon
time and location for the purpose of resolving such dispute;

                           (d)        If,
within a further period of [*] ([*])[*], the dispute has not been resolved or
if, for any reason, the required meeting has not been held, then the same shall
be submitted by the Parties to arbitration in Seattle, Washington in accordance
with the then-current commercial arbitration rules of the American Arbitration
Association (“AAA”) except as otherwise provided herein.  The Parties shall choose, by mutual
agreement, one (1) arbitrator within [*] ([*])[*] of receipt of notice of the intent
to arbitrate.  If no arbitrator is
appointed within the times herein provided or any extension of time that is
mutually agreed upon, the AAA shall make such appointment within [*] ([*]) [*]
of such failure.  The judgment rendered
by the arbitrator shall include costs of arbitration, reasonable attorneys’
fees and reasonable costs for expert and other witnesses.  Nothing in this Agreement shall be deemed as
preventing either Party from seeking injunctive relief (or any other
provisional remedy).  If the issues in
dispute involve scientific, technical or commercial matters, any arbitrator
chosen hereunder shall have educational training and/or industry experience
sufficient to demonstrate a reasonable level of relevant scientific, medical
and industry knowledge.

                           (e)         In
the event of a dispute regarding any payments owing under this Agreement, all
undisputed amounts shall be paid promptly when due and the balance, if any,
promptly after resolution of the dispute.

             22.4.     Entire Agreement.

             This Agreement contains the entire understanding of the
Parties with respect to the subject matter hereof.  All express or implied agreements and understandings, either oral
or written, heretofore made are expressly superseded by this Agreement.  This Agreement may be amended, or any term
hereof modified, only by a written instrument duly executed by both Parties
hereto.

             22.5.     Independent Contractors.

             SGI and EOS each acknowledge that they shall be
independent contractors and that the relationship between the two Parties shall
not constitute a partnership, joint venture or agency.  Neither SGI nor EOS shall have the authority
to make any statements, representations or commitments of any kind, or to take
any action, which shall be binding on the other Party, without the prior
consent of the other Party to do so.

             22.6.     Affiliates

             Each Party shall cause its respective Affiliates to
comply fully with the provisions of this Agreement to the extent such
provisions specifically relate to, or are intended to specifically relate to,
such Affiliates, as though such Affiliates were expressly named as joint
obligors hereunder.

             22.7.     Waiver.

             The waiver by either Party hereto of any right hereunder
or the failure to perform or of a breach by the other Party shall not be deemed
a waiver of any other right hereunder or of any other breach or failure by said
other Party whether of a similar nature or otherwise.

             22.8.     Counterparts.

             This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

             IN WITNESS WHEREOF, the Parties have executed this
Agreement as of the date first set forth above.

	 	SEATTLE
  GENETICS, INC.
	 	 
	 	By:	/s/
  CLAY B. SIEGALL
	 	 	

	 	Name:	CLAY
  B. SIEGALL
	 	 	

	 	Title:	PRESIDENT
  and CSO
	 	 	

	 	 	 
	 	EOS
  BIOTECHNOLOGY, INC.
	 	 
	 	By:	/s/
  DAVID W. MARTIN, JR.
	 	 	

	 	Name:	DAVID
  W. MARTIN, JR.
	 	 	

	 	Title:	PRESIDENT
  and CEO
	 	 	

 

	

	[*]  Confidential Treatment Requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}]]